Accueil   Agenda - News   Toutes les news ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

 

 

 

ROCKVILLE, Md., Nov. 19, 2018 /PRNewswire/ -- ABL, Inc. (ABL), a global contract manufacturing organization that advances leading vaccines and therapies from clinical development to the commercial market, is pleased to announce a strategic acquisition through its wholly-owned subsidiary, ABL Europe SAS (ABL Europe), of a 6,500 m2 GMP manufacturing site located in Lyon, France. ABL Europe provides dedicated viral vector GMP contract manufacturing (CMO) services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch. Maintaining synergy with ABL's contract development and virus manufacturing operations in Strasbourg and Rockville, the new Lyon site will focus on providing ABL's clients with increased options and capacities in response to the rapid growth in demand for the production of viral vectors observed in the immuno-oncolytic and gene therapy space.

 

 

 

Read the press release

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer